Artemisinin resistance-modelling the potential human and economic costs

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Lubell, Yoel ^a,b   Dondorp, Arjen ^a,b   Guerin, Philippe J ^b,c   Drake, Tom ^a,b   Meek, Sylvia ^d   Ashley, Elizabeth ^a,b   Day, Nicholas P J ^a,b   White, Nicholas J ^a,b   White, Lisa J ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MALARIA CONSORTIUM   (United Kingdom)

Author keywords

Anti malarial resistance; Artemisinins; Economics; Malaria

Indexed keywords

AMODIAQUINE; ARTEMISININ; ARTESUNATE; CHLOROQUINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ARTICLE; CAMBODIA; DECISION TREE; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; HEALTH CARE COST; HUMAN; INCIDENCE; INFECTION RESISTANCE; MALARIA; MORBIDITY; MORTALITY; PRODUCTIVITY; RETREATMENT; COMBINATION DRUG THERAPY; DRUG RESISTANCE; ECONOMICS; MALARIA, FALCIPARUM; PROCEDURES;

ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HUMANS; MALARIA, FALCIPARUM; QUININE;

EID: 84989243768     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-452     Document Type: Article

References (37)

1. O'Meara WP, Mangeni JN, Steketee R, Greenwood B: Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis 2010, 10:545-555.
2. Sawa P, Shekalaghe SA, Drakeley CJ, Sutherland CJ, Mweresa CK, Baidjoe AY, Manjurano A, Kavishe RA, Beshir KB, Yussuf RU, Omar SA, Hermsen CC, Okell L, Schallig HD, Sauerwein RW, Hallett RL, Bousema T: Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 2013, 207:1637-1645.
3. Dondorp A, Nosten F, Stepniewska K, Day N, White N: Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005, 366:717-725.
4. Imwong M, Dondorp AM, Nosten F, Yi P, Mungthin M, Hanchana S, Das D, Phyo AP, Lwin KM, Pukrittayakamee S, Lee SJ, Saisung S, Koecharoen K, Nguon C, Day NP, Socheat D, White NJ: Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob Agents Chemother 2010, 54:2886-2892.
5. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009, 361:455-467.
6. Saralamba S, Pan-Ngum W, Maude RJ, Lee SJ, Tarning J, Lindegardh N, Chotivanich K, Nosten F, Day NP, Socheat D, White NJ, Dondorp AM, White LJ: Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 2011, 108:397-402.
7. Pongtavornpinyo W, Hastings IM, Dondorp A, White LJ, Maude RJ, Saralamba S, Day NP, White NJ, Boni MF: Probability of emergence of antimalarial resistance in different stages of the parasite life cycle. Evol Appl 2009, 2:52-61.
8. Maude RJ, Pontavornpinyo W, Saralamba S, Aguas R, Yeung S, Dondorp AM, Day NP, White NJ, White LJ: The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J 2009, 8:31.
9. White LJ, Lubell Y, Meek S, White NJ, Day NP, Nosten F, Ashley E, Socheat D, Nguon C, Dondorp A: Malaria in the Asia-Pacific: modelling the current and potential impact of artemisinin resistance and its containment. In Malaria 2012 Saving Lives in the Asia Pacific. 2012 (AUSAID ed.2012).
10. Carrara VI, Lwin KM, Phyo AP, Ashley E, Wiladphaingern J, Sriprawat K, Rijken M, Boel M, McGready R, Proux S, Chu C, Singhasivanon P, White N, Nosten F: Malaria burden and artemisinin resistance in the mobile and migrant population on the thai-myanmar border, 1999-2011: an observational study. PLoS Med 2013, 10:e1001398.
11. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, Ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F: Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012, 379:1960-1966.
12. Q&A on artemisinin resistance. [http://www.who.int/malaria/media/artemisinin-resistance-qa/en/]
13. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D: A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014, 505:50-55.
14. WHO: Global Report on Antimalarial Drug Efficacy and Drug Resistance: 2000-2010. In Geneva: World Health Organization; 2010.
15. Das D, Tripura R, Phyo AP, Lwin KM, Tarning J, Lee SJ, Hanpithakpong W, Stepniewska K, Menard D, Ringwald P, Silamut K, Imwong M, Chotivanich K, Yi P, Day NP, Lindegardh N, Socheat D, Nguon C, White NJ, Nosten F, Dondorp AM: Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. Clin Infect Dis 2013, 56:e48-58.
16. Lubell Y, Staedke SG, Greenwood B, Kamya MR, Molineaux M, Newton PN, Reyburn H, Snow R, D'Alessandro U, English M, Day N, Kremsner P, Dondorp A, Mbacham W, Dorsey G, Owusu-Agyei S, Maitland K, Krishna S, Newton CR, Pasvol G, Taylor T, von Seidlein L, White NJ, Binka F, Mills A, Whitty CJ: Likely health outcomes for untreated acute febrile illness in the tropics in decision and economic models; a Delphi survey. PLoS One 2011, 6:e17439.
17. Pfeil J, Borrmann S, Tozan Y: Dihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in African children: a cost-effectiveness analysis. PLoS One 2014, 9:e95681.
18. Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein L, Mokuolu OA, Nansumba M, Gesase S, Kent A, Mtove G, Olaosebikan R, Ngum WP, Fanello CI, Hendriksen I, Day NP, White NJ, Yeung S: Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa. Bull World Health Organ 2011, 89:504-512.
19. Mulligan JA, Mandike R, Palmer N, Williams H, Abdulla S, Bloland P, Mills A: The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania. Trop Med Int Health 2006, 11:452-461.
20. GDP per capita (current US$). [http://data.worldbank.org/indicator/NY.GDP. PCAP.CD]
21. Chuma J, Okungu V, Molyneux C: The economic costs of malaria in four Kenyan districts: do household costs differ by disease endemicity? Malar J 2010, 9:149.
22. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L: The friction cost method for measuring indirect costs of disease. J Health Econ 1995, 14:171-189.
23. van den Hout WB: The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis 2010, 69(Suppl 1):i89-91.
24. WHO: World Malaria Report 2012. Geneva: World Health Organization; 2012.
25. Littrell M, Gatakaa H, Evance I, Poyer S, Njogu J, Solomon T, Munroe E, Chapman S, Goodman C, Hanson K, Zinsou C, Akulayi L, Raharinjatovo J, Arogundade E, Buyungo P, Mpasela F, Adjibabi CB, Agbango JA, Ramarosandratana BF, Coker B, Rubahika D, Hamainza B, Shewchuk T, Chavasse D, O'Connell KA: Monitoring fever treatment behaviour and equitable access to effective medicines in the context of initiatives to improve ACT access: baseline results and implications for programming in six African countries. Malar J 2011, 10:327.
26. Littrell M, Gatakaa H, Phok S, Allen H, Yeung S, Chuor CM, Dysoley L, Socheat D, Spiers A, White C, Shewchuk T, Chavasse D, O'Connell KA: Case management of malaria fever in Cambodia: results from national anti-malarial outlet and household surveys. Malar J 2011, 10:328.
27. Tougher S, Ye Y, Amuasi JH, Kourgueni IA, Thomson R, Goodman C, Mann AG, Ren R, Willey BA, Adegoke CA, Amin A, Ansong D, Bruxvoort K, Diallo DA, Diap G, Festo C, Johanes B, Juma E, Kalolella A, Malam O, Mberu B, Ndiaye S, Nguah SB, Seydou M, Taylor M, Rueda ST, Wamukoya M, Arnold F, Hanson K: Effect of the Affordable Medicines Facility-malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data. Lancet 2012, 380:1916-1926.
28. O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, Solomon T, Goodman C, Hanson K, Zinsou C, Akulayi L, Raharinjatovo J, Arogundade E, Buyungo P, Mpasela F, Adjibabi CB, Agbango JA, Ramarosandratana BF, Coker B, Rubahika D, Hamainza B, Chapman S, Shewchuk T, Chavasse D: Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J 2011, 10:326.
29. The DHS Program: demographic and health surveys. [http://dhsprogram. com/Data/.
30. Mapping the cost of widespread artemisinin resistance. [http://goo.gl/oTg8rR]
31. Chima RI, Goodman CA, Mills A: The economic impact of malaria in Africa: a critical review of the evidence. Health Policy 2003, 63:17-36.
32. Gallup JL, Sachs JD: The economic burden of malaria. Am J Trop Med Hyg 2001, 64:85-96.
33. Malaney P, Spielman A, Sachs J: The malaria gap. Am J Trop Med Hyg 2004, 71:141-146.
34. Nayyar GM, Breman JG, Newton PN, Herrington J: Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Di 2012, 12:488-496.
35. Tabernero P, Fernandez FM, Green M, Guerin PJ, Newton PN: Mind the gaps-the epidemiology of poor-quality anti-malarials in the malarious world-analysis of the WorldWide Antimalarial Resistance Network database. Malar J 2014, 13:139.
36. MacPherson DW, Gushulak BD, Baine WB, Bala S, Gubbins PO, Holtom P, Segarra-Newnham M: Population mobility, globalization, and antimicrobial drug resistance. Emerg Infect Dis 2009, 15:1727-1732.
37. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD: Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012, 379:413-431.